|
業務類別
|
-- |
|
業務概覽
|
Seelos Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing products that address unmet needs in Central Nervous System (CNS) disorders and other rare disorders. Its product pipeline includesSLS-002, SLS-005, SLS-004, SLS-007, and SLS-009. |
| 公司地址
| 300 Park Avenue, 2nd Floor, New York, NY, USA, 10022 |
| 電話號碼
| +1 646 293-2100 |
| 傳真號碼
| -- |
| 公司網頁
| https://www.seelostherapeutics.com |
| 員工數量
| 16 |
| Mr. Michael Golembiewski |
Chief Financial Officer and Principal Accounting Officer |
-- |
20/08/2024 |
| Dr. Raj Mehra, PhD |
Director, Chief Executive Officer and President |
-- |
20/08/2024 |
|
|
| Mr. Richard W. Pascoe |
Chairman of the Board |
20/08/2024 |
| Dr. Brian Lian, PhD |
Independent Director |
20/08/2024 |
| Dr. Margaret Dalesandro, PhD |
Independent Director |
20/08/2024 |
| Dr. Raj Mehra, PhD |
Director, Chief Executive Officer and President |
20/08/2024 |
|
|
|
|
